Comparative Pharmacology
Head-to-head clinical analysis: INVANZ versus MEROPENEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVANZ versus MEROPENEM.
INVANZ vs MEROPENEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ertapenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
Meropenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP 2 and PBP 3, leading to cell death.
1 g IV or IM once daily
1-2 g IV every 8 hours, infused over 15-30 minutes; typical dose 1 g q8h for complicated infections. Extended infusion over 3 hours may be used for resistant organisms.
None Documented
None Documented
Terminal elimination half-life approximately 4 hours; prolonged to approximately 8 hours in mild to moderate renal impairment (CrCl 30-59 mL/min) and to 14 hours in severe renal impairment (CrCl <30 mL/min); clinical context: requires dosage adjustment in renal impairment.
Clinical Note
moderateMeropenem + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Meropenem."
Clinical Note
moderateMeropenem + Valproic acid
"The serum concentration of Valproic acid can be decreased when it is combined with Meropenem."
Clinical Note
moderateMeropenem + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Meropenem."
1.0-1.5 hours in adults with normal renal function; prolonged to 4-6 hours in moderate renal impairment (CrCl 10-50 mL/min) and up to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
Renal: ~80% unchanged in urine; biliary/fecal: ~10% as unchanged drug and the open-ring metabolite; minor hepatic metabolism.
Renal: 70% unchanged via glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: ~2%.
Category C
Category A/B
Carbapenem Antibiotic
Carbapenem Antibiotic